Cel­gene’s up­date on its big Crohn’s drug? Trust us, we’re do­ing fine

Cel­gene in­sists that an in­ter­im analy­sis of its close­ly-watched study for GED-0301 (mon­gersen) was “en­cour­ag­ing,” but it failed to show any of its cards to­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER